NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Health Information Services · USD

Simulations Plus, Inc. (SLP) Stock Analysis

Simulations Plus, Inc. (SLP) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

SLP

$18.43

+$0.01 (+0.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SLP with… →

SLP Key Statistics

As of Sep 4, 2026
Trading
Open
$18.44
Previous Close
$18.42
Day's Range
18.42–18.45
52-Week Range
11.09–21.01
Volume
79.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.33
Valuation
Market Cap
$372.74M
P/E Ratio
46.08
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
20.88
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
9.88
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.54
EPS (ttm)Profit attributable to each share over the last twelve months.
0.40
Financials (FY)
Revenue (FY)
$79.18M+13.09%
Net Income (FY)
−$64.72M−750.17%
Profit marginThe share of revenue left as profit after all costs and taxes.
9.88%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
20.22M
1-Year Return
+30.52%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
422.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.10%
2025−34.64%
2024−37.40%
2023+23.09%
2022−22.28%
2021−33.93%
2020+148.64%
2019+47.45%
2018+25.26%
2017+69.51%
2016 (partial year)+18.21%

As of September 4, 2026.

SLP Revenue and Earnings by Fiscal Year

FY ends August
Fiscal yearRevenueNet incomeNet margin
2025$79.18M−$64.72M−81.7%
2024$70.01M$9.95M14.2%
2023$59.58M$9.96M16.7%
2022$53.91M$12.48M23.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$79.18M$46.22M$6.49M−$64.72M−81.7%
2024$70.01M$43.15M$6.13M$9.95M14.2%
2023$59.58M$47.95M$9.23M$9.96M16.7%
2022$53.91M$43.08M$14.91M$12.48M23.2%

Annual figures as reported, in the company's reporting currency. As of August 31, 2025.

SLP Valuation vs Health Information Services Median

Median of 53 stocks
MetricSLPHealth Information Services medianvs median
P/E46.0841.1312% above
P/S ratio4.542.6671% above
Profit margin9.88%0.00%9.9 pts above

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Simulations Plus, Inc. (SLP) at $372.74M. It is classified in the Health Information Services industry, within the Healthcare sector. Headcount on file is 212.

The 52-week range on file runs from $11.09 to $21.01. SLP last closed at $18.43 on September 4, 2026. That is +$0.01 (+0.05%) against the previous close. The latest close sits 66.19% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $79.18M. That is +13.09% against the prior fiscal year, when revenue was $70.01M. The same year closed with a net loss of $64.72M. The reported profit margin is 9.88%. That is 9.9 percentage points above the Health Information Services median of 0%. Trailing earnings per share are 0.4.

Across the 4 fiscal years on file, revenue moves from $53.91M in 2022 to $79.18M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

SLP trades at a trailing price-to-earnings ratio of 46.08. That is 12.04% above the Health Information Services median of 41.13. The forward P/E on file is 20.88. The PEG ratio, which sets the P/E against expected earnings growth, reads 9.88. Measured against sales, the shares trade at 4.54 times revenue. On price-to-sales that is 70.84% above the Health Information Services median of 2.66. 53 Health Information Services companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.33. Daily returns over the trailing 10 years annualize to a volatility of 48.26%. The trailing one-year price return is +30.52%. Measured over 10 years, that is +8.15% a year compounded.

Growth & Income

The record shows no dividend for SLP.

Across the complete calendar years on file, 2020 returned +148.64% and 2024 returned −37.40%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +1.10% year to date.

Peer Comparison

Simulations Plus, Inc. (SLP) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Simulations Plus, Inc. SLP $372.74M 46.1
Veeva Systems Inc. VEEV $44.54B 45.0
BrightSpring Health Services, Inc. BTSG $12.02B 54.7
Tempus AI, Inc. TEM $11.66B —

The Health Information Services industry average P/E ratio is 41.1x. Simulations Plus, Inc. trades at a P/E of 46.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

 BTSG

BrightSpring Health Services, Inc.

$12.02B

 TEM

Tempus AI, Inc.

$11.66B

 HQY

HealthEquity, Inc.

$7.95B

 HNGE

Hinge Health, Inc.

$7.45B

 WAY

Waystar Holding Corp.

$4.81B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Simulations Plus, Inc.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

Visit website →